Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-02 Anti-androgens
| Cyproterone Acetate |
|
Formulary
|
Tablets 50mg For indications other than oncology |
 MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma |
|
| Finasteride |
|
Formulary
|
tablets 5mg Finasteride is the preferred 5α-reductase inhibitor for Benign Prostatic Hyperplasia (BPH). |
|
LSCMMG: Finasteride MHRA: Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment) |
|
|
Links
LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG Shared care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Finasteride
- LSCMMG: SHARED CARE GUIDELINE: Testosterone For hypogonadism due to testosterone deficiency in adult men
- LSCMMG: SHARED CARE GUIDELINE: Testosterone For hypogonadism due to testosterone deficiency in adult men
- LSCMMG: Testosterone (Testim® ) NMR
- LSCMMG: Testosterone (transdermal) NMR
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- LSCMMG:Testosterone (transdermal) As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective shared care guideline
- MHRA Drug Safety update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA: Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
- MHRA: Topical testosterone (Testogel): risk of harm to children following accidental exposure
- MHRA: Topical testosterone (Testogel): risk of harm to children following accidental exposure
- SHARED CARE GUIDELINE :As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective